Abbonarsi

Coenzyme Q10 deficiency in patients with hereditary hemochromatosis - 11/11/21

Doi : 10.1016/j.clinre.2021.101624 
Manuela R. Martinefski a, María F. Yamasato b, María B. Di Carlo c, Jorge R. Daruich b, Valeria P. Tripodi a, d,
a Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Tecnología Farmacéutica, Buenos Aires, Argentina 
b Universidad de Buenos Aires, Facultad de Medicina, División de Gastroenterología, Sección Hepatología, Hospital de Clínicas José de San Martin, Buenos Aires, Argentina 
c Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martin, Buenos Aires, Argentina 
d Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Argentina 

Corresponding author at: Professor of Pharmacy and Biochemistry, Junín 956, 5th Floor, CABA, Buenos Aires, Argentina.Professor of Pharmacy and BiochemistryJunín 956, 5th Floor, CABABuenos AiresArgentina

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 7
Iconografia 1
Video 0
Altro 0

Highlights

A decrease in plasma coenzyme Q10 (CoQ10) is described for the first time in patients with no treated hereditary hemochromatosis (HH).
The decrease in plasma CoQ10 was independent of the patient HFE genotype, cirrhosis occurrence, aminotransferases levels or iron status.
CoQ10 supplementation could be a complementary therapeutic, besides phlebotomy, to prevent oxidative stress-mediated cellular damage in HH.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Aim

Hereditary hemochromatosis (HH) is a group of inherited disorders that causes a slow and progressive iron deposition in diverse organs, particularly in the liver. Iron overload induces oxidative stress and tissue damage. Coenzyme Q10 (CoQ10) is a cofactor in the electron-transport chain of the mitochondria, but it is also a potent endogenous antioxidant. CoQ10 interest has recently grown since various studies show that CoQ10 supplementation may provide protective and safe benefits in mitochondrial diseases and oxidative stress disorders. In the present study we sought to determine CoQ10 plasma level in patients recently diagnosed with HH and to correlate it with biochemical, genetic, and histological features of the disease. Methods: Plasma levels of CoQ10, iron, ferritin, transferrin and vitamins (A, C and E), liver tests (transaminases, alkaline phosphatase and bilirubin), and histology, as well as three HFE gene mutations (H63D, S654C and C282Y), were assessed in thirty-eight patients (32 males, 6 females) newly diagnosed with HH without treatment and in twenty-five age-matched normolipidemic healthy subjects with no HFE gene mutations (22 males, 3 females) and without clinical or biochemical signs of iron overload or liver diseases.

Results

Patients with HH showed a significant decrease in CoQ10 levels respect to control subjects (0.31 ± 0.03 µM vs 0.70 ± 0.06 µM, p < 0.001, respectively) independently of the genetic mutation, cirrhosis, transferrin saturation, ferritin level or markers of hepatic dysfunction. Although a decreasing trend in CoQ10 levels was observed in patients with elevated iron levels, no correlation was found between both parameters in patients with HH. Vitamins C and A levels showed no changes in HH patients. Vitamin E was significantly decreased in HH patients (21.1 ± 1.3 µM vs 29.9 ± 2.5 µM, p < 0.001, respectively), but no correlation was observed with CoQ10 levels. Conclusion: The decrease in CoQ10 levels found in HH patients suggests that CoQ10 supplementation could be a safe intervention strategy complementary to the traditional therapy to ameliorate oxidative stress and further tissue damage induced by iron overload.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : HH, ROS, LIP, CoQ10, ALT, AST, ALP, HPLC–UV

Keywords : Coenzyme Q10, Oxidative stress, Ubiquinone, Hemochromatosis, Iron overload, supplementation


Mappa


© 2021  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 45 - N° 6

Articolo 101624- Novembre 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era
  • Charlotte Bouzbib, Philippe Cluzel, Philippe Sultanik, Brigitte Bernard-Chabert, Julien Massard, Hedi Benosman, Maxime Mallet, Simona Tripon, Filomena Conti, Dominique Thabut, Marika Rudler
| Articolo seguente Articolo seguente
  • The Ability of the Framingham Steatosis Index (FSI) to Predict Non-alcoholic Fatty Liver Disease (NAFLD): A Cohort Study
  • Nima Motamed, Mehdi Nikkhah, Mohammad Hadi Karbalaie Niya, Mahmoodreza khoonsari, Dhayaneethie Perumal, G. Hossein Ashrafi, Amir Hossein Faraji, Mansooreh Maadi, Hossein Ajdarkosh, Fahimeh Safarnezhad Tameshkel, Maziar Moradi-Lakeh, Seyyed Mohammad Miri, Shahram Arsang-Jang, Farhad Zamani

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.